Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yongjie Xie"'
Autor:
Chunhua She, Chao Wu, Weihua Guo, Yongjie Xie, Shouyi Li, Weishuai Liu, Chao Xu, Hui Li, Pei Cao, Yanfang Yang, Xiuchao Wang, Antao Chang, Yukuan Feng, Jihui Hao
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-22 (2023)
Abstract Background Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1,
Externí odkaz:
https://doaj.org/article/35cb9655f284424ab326102f407ef4cd
Autor:
Tianxing Zhou, Quan Man, Xueyang Li, Yongjie Xie, Xupeng Hou, Hailong Wang, Jingrui Yan, Xueqing Wei, Weiwei Bai, Ziyun Liu, Jing Liu, Jihui Hao
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 3, Pp 196-217 (2023)
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated with the outcome of patients with PDAC, but the correlations have been i
Externí odkaz:
https://doaj.org/article/d6a9e7f1a8244667bb00cdc100d2c6c3
Autor:
Yongjie Xie, Yang Liu, Jinsheng Ding, Guangming Li, Bo Ni, Huifang Pang, Xin Hu, Liangliang Wu
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 10 (2022)
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignant tumors worldwide and has poor prognosis. DEAD box proteins31 (DDX31) participate in cellular processes involving RNA secondary structure changes. However, the funct
Externí odkaz:
https://doaj.org/article/0a5e12ddd65e4178aa62d7738f7c6ae3